News & Updates

Failed spinal anaesthesia: Reasons, prevention and management

16 May 2025 by

In an interview with MIMS Doctor, Professor Ki-Jinn Chin of the Department of Anesthesiology and Pain Medicine at University of Toronto, Toronto, Ontario, Canada, discusses potential reasons behind failed spinal anaesthesia, suggests possible ways of maximizing its success rate, and offers tips on how to manage complications.

Failed spinal anaesthesia: Reasons, prevention and management

16 May 2025

Long-term oral progestogen therapy effective, well tolerated in endometriosis management

19 Mar 2025 by

Endometriosis is a chronic disease, which requires interventions that are both effective and well tolerated in the long term. Dr Tak-Keung Sum, Specialist in Obstetrics and Gynaecology in private practice in Hong Kong, reviews clinical and real-world evidence on the long-term efficacy and safety of an oral progestogen, dienogest (Visanne^®, Bayer), and shares his personal experience in managing endometriosis across different patient profiles.

Long-term oral progestogen therapy effective, well tolerated in endometriosis management

19 Mar 2025

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

12 Feb 2025 by

Occurring in up to 20 percent of breast cancers, HER2 overexpression is linked to high disease recurrence and poor survival outcomes. At the Hong Kong Breast Cancer Foundation (HKBCF) Annual Breast Cancer Updates 2024 meeting, Professor Matteo Lambertini from University of Genova, Italy, discussed the benefits of adding pertuzumab to trastuzumab and chemotherapy in managing HER2-positive (HER2+) early breast cancer (EBC), while a real-world case was shared by Dr Josephine Tsang from Queen Mary Hospital, Hong Kong.

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

12 Feb 2025

Bivalent RSV vaccine effective with favourable safety profile in infants through maternal immunization

16 Sep 2024

Respiratory syncytial virus (RSV) infection is a common cause of acute lower respiratory tract disease (LRTD) and a leading cause of hospitalization in infants. In Hong Kong, the single-dose RSV prefusion F protein–based (RSVpreF) vaccine, indicated for active immunization of pregnant individuals at a gestational age of 32–36 weeks, is now available for prevention of LRTD and severe LRTD caused by RSV in infants ≤6 months of age. This article discusses the burden of RSV infections and the efficacy and safety of the RSVpreF vaccine specifically against medically attended severe RSV-associated LRTD in infants, which demonstrated an efficacy of 81.8 percent at 90 days after birth and 69.4 percent at 180 days after birth in a pivotal trial.

Bivalent RSV vaccine effective with favourable safety profile in infants through maternal immunization

16 Sep 2024

Dual-indication bivalent RSV vaccine now available in HK: Maternal immunization data

20 Aug 2024

Respiratory syncytial virus (RSV) prefusion F protein–based (RSVpreF) vaccine, a single-dose bivalent vaccine against RSV A and RSV B, is now available in Hong Kong for prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to 6 months of age through active immunization of pregnant individuals at a gestational age of 32–36 weeks, and for prevention of LRTD caused by RSV in individuals aged ≥60 years.

Dual-indication bivalent RSV vaccine now available in HK: Maternal immunization data

20 Aug 2024

SGO 2024: Unprecedented survival benefits with dostarlimab in advanced endometrial cancer

13 Jun 2024 by

At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer held in San Diego, US, researchers presented updated results from the two-part, phase III ENGOT-EN6-NSGO/GOG-3031/RUBY trial, demonstrating statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) associated with dostarlimab-based combinations in patients with primary advanced or recurrent endometrial cancer (EC).

SGO 2024: Unprecedented survival benefits with dostarlimab in advanced endometrial cancer

13 Jun 2024

DUO-E: Durvalumab combo ups survival in advanced endometrial cancer, including in pMMR patients

13 Jun 2024 by

At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, Professor Jean-François Baurain of the Cliniques Universitaires Saint-Luc in Brussels, Belgium, and Dr Hye-Sook Chon of the H. Lee Moffitt Cancer Center in Tampa, Florida, US, shared positive updates from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial (DUO-E), which demonstrated survival benefits associated with adding the immune checkpoint inhibitor, durvalumab, with or without the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, to standard platinum-based chemotherapy in patients with advanced endometrial cancer, including those with mismatch repair–proficient (pMMR) tumours.

DUO-E: Durvalumab combo ups survival in advanced endometrial cancer, including in pMMR patients

13 Jun 2024

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

19 Mar 2021 by

In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

19 Mar 2021

News & Updates

Filter by Specialty:

Specialty:

Failed spinal anaesthesia: Reasons, prevention and management

Failed spinal anaesthesia: Reasons, prevention and management

Long-term oral progestogen therapy effective, well tolerated in endometriosis management

Long-term oral progestogen therapy effective, well tolerated in endometriosis management

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

Bivalent RSV vaccine effective with favourable safety profile in infants through maternal immunization

Bivalent RSV vaccine effective with favourable safety profile in infants through maternal immunization

Dual-indication bivalent RSV vaccine now available in HK: Maternal immunization data

Dual-indication bivalent RSV vaccine now available in HK: Maternal immunization data

SGO 2024: Unprecedented survival benefits with dostarlimab in advanced endometrial cancer

SGO 2024: Unprecedented survival benefits with dostarlimab in advanced endometrial cancer

DUO-E: Durvalumab combo ups survival in advanced endometrial cancer, including in pMMR patients

DUO-E: Durvalumab combo ups survival in advanced endometrial cancer, including in pMMR patients

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib